The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity
Open accessAbstract
Expression of eukaryotic translation initiation factor 4E (eIF4E) is commonly elevated in human and experimental cancers, promoting angiogenesis and tumor growth. Elevated eIF4E levels selectively increase translation of growth factors important in malignancy (e.g., VEGF, cyclin D1) and is thereby an attractive anticancer therapeutic target. Yet to date, no eIF4E-specific therapy has been developed. Herein we report development of eIF4E-specific antisense oligonucleotides (ASOs) designed to have the necessary tissue stability and nuclease resistance required for systemic anticancer therapy. In mammalian cultured cells, these ASOs specifically targeted the eIF4E mRNA for destruction, repressing expression of eIF4E-regulated proteins (e.g., VEGF, cyclin D1, survivin, c-myc, Bcl-2), inducing apoptosis, and preventing endothelial cells from forming vessel-like structures. Most importantly, intravenous ASO administration selectively and significantly reduced eIF4E expression in human tumor xenografts, significantly suppressing tumor growth. Because these ASOs also target murine eIF4E, we assessed the impact of eIF4E reduction in normal tissues. Despite reducing eIF4E levels by 80% in mouse liver, eIF4E-specific ASO administration did not affect body weight, organ weight, or liver transaminase levels, thereby providing the first in vivo evidence that cancers may be more susceptible to eIF4E inhibition than normal tissues. These data have prompted eIF4E-specific ASO clinical trials for the treatment of human cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genes Expressed in Human Tumor Endothelium
Croix, B. S., Rago, C., Velculescu, V., Traverso, G., Romans, K. E., Montgomery, E., Lal, A., Riggins, G. J., Lengauer, C., Vogelstein, B., et al. (2000) · Science · doi:10.1126/science.289.5482.1197 · Cited by 1,845
The tor pathway: a target for cancer therapy
Bjornsti, M.-A., & Houghton, P. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1362 · Cited by 1,314
Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap
Lazaris-Karatzas, A., Montine, K. S., & Sonenberg, N. (1990) · Nature · doi:10.1038/345544a0 · Cited by 956
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy
Wendel, H.-G., Stanchina, E. D., Fridman, J. S., Malina, A., Ray, S., Kogan, S., Cordon-Cardo, C., Pelletier, J., & Lowe, S. W. (2004) · Nature · doi:10.1038/nature02369 · Cited by 951
Gingras, A.-C., Kennedy, S. G., O'Leary, M. A., Sonenberg, N., & Hay, N. (1998) · Genes & Development · doi:10.1101/gad.12.4.502 · Cited by 886
Phosphorylation of the Translational Repressor PHAS-I by the Mammalian Target of Rapamycin
Brunn, G. J., Hudson, C. C., Sekulić, A., Williams, J. M., Hosoi, H., Houghton, P. J., Lawrence, J. C., & Abraham, R. T. (1997) · Science · doi:10.1126/science.277.5322.99 · Cited by 846
eIF-4E expression and its role in malignancies and metastases
De Benedetti, A., & Graff, J. R. (2004) · Oncogene · doi:10.1038/sj.onc.1207545 · Cited by 728
Self-citationThe translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis
Ruggero, D., Montanaro, L., Ma, L., Xu, W., Londei, P., Cordon-Cardo, C., & Pandolfi, P. P. (2004) · Nature Medicine · doi:10.1038/nm1042 · Cited by 586
Jiang, B.-H., Zheng, J. Z., Aoki, M., & Vogt, P. K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.040560897 · Cited by 528
eIF4E – from translation to transformation
Mamane, Y., Petroulakis, E., Rong, L., Yoshida, K., Ler, L. W., & Sonenberg, N. (2004) · Oncogene · doi:10.1038/sj.onc.1207549 · Cited by 449
Graff, J. R., McNulty, A. M., Hanna, K. R., Konicek, B. W., Lynch, R. L., Bailey, S. N., Banks, C., Capen, A., Goode, R., Lewis, J. E., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0071 · Cited by 442
Self-citationRousseau, D., Kaspar, R., Rosenwald, I., Gehrke, L., & Sonenberg, N. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.3.1065 · Cited by 399
Graff, J. R., Konicek, B. W., McNulty, A. M., Wang, Z., Houck, K., Allen, S., Paul, J. D., Hbaiu, A., Goode, R. G., Sandusky, G. E., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003145200 · Cited by 378
Self-citationAkt-regulated pathways in prostate cancer
Majumder, P. K., & Sellers, W. R. (2005) · Oncogene · doi:10.1038/sj.onc.1209096 · Cited by 344
Avdulov, S., Li, S., Michalek, V., Burrichter, D., Peterson, M., Perlman, D. M., Manivel, J. C., Sonenberg, N., Yee, D., Bitterman, P. B., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.05.024 · Cited by 340
An in vitro model of angiogenesis: Basic features
Bishop, E. T., Bell, G. T., Bloor, S., Broom, I. J., Hendry, N. F. K., & Wheatley, D. N. (1999) · Angiogenesis · doi:10.1023/a:1026546219962 · Cited by 307
eIF4E is a central node of an RNA regulon that governs cellular proliferation
Culjkovic, B., Topisirovic, I., Skrabanek, L., Ruiz-Gutierrez, M., & Borden, K. L. B. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200607020 · Cited by 293
Pharmacokinetic Properties of 2′-O-(2-Methoxyethyl)-Modified Oligonucleotide Analogs in Rats
Geary, R. S., Watanabe, T. A., Truong, L., Freier, S., Lesnik, E. A., Sioufi, N. B., Sasmor, H., Manoharan, M., & Levin, A. A. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38831-7 · Cited by 288
Rosenwald, I. B., Lazaris-Karatzas, A., Sonenberg, N., & Schmidt, E. V. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.12.7358 · Cited by 287
Rosenwald, I. B., Kaspar, R., Rousseau, D., Gehrke, L., Leboulch, P., Chen, J.-J., Schmidt, E. V., Sonenberg, N., & London, I. M. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.36.21176 · Cited by 269
Zhang, H., Cook, J., Nickel, J., Yu, R., Stecker, K., Myers, K., & Dean, N. M. (2000) · Nature Biotechnology · doi:10.1038/78475 · Cited by 268
Self-citationChi, K. N., Eisenhauer, E., Fazli, L., Jones, E. C., Goldenberg, S. L., Powers, J., Tu, D., & Gleave, M. E. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji252 · Cited by 266
Antisense oligonucleotide-based therapeutics for cancer
Dean, N. M., & Bennett, C. F. (2003) · Oncogene · doi:10.1038/sj.onc.1207231 · Cited by 234
Self-citationEpigenetic Activation of a Subset of mRNAs by eIF4E Explains Its Effects on Cell Proliferation
Mamane, Y., Petroulakis, E., Martineau, Y., Sato, T.-A., Larsson, O., Rajasekhar, V. K., & Sonenberg, N. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000242 · Cited by 224
The eIF4E-binding proteins 1 and 2 are negative regulators of cell growth.
Rousseau, D. L., Gingras, A., Pause, A., & Sonenberg, N. (1996) · PubMed · Cited by 220
Shantz, L. M., & Pegg, A. E. (1994) · PubMed · Cited by 208
Pak-1 Expression Increases with Progression of Colorectal Carcinomas to Metastasis
Carter, J. H., Douglass, L. E., Deddens, J. A., Colligan, B. M., Bhatt, T. R., Pemberton, J. O., Konicek, S., Hom, J., Marshall, M., & Graff, J. R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0210 · Cited by 185
Self-citationPolunovsky, V. A., Rosenwald, I. B., Tan, A. T., White, J., Chiang, L., Sonenberg, N., & Bitterman, P. B. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.11.6573 · Cited by 165
Zimmer, S. G., Benedetti, A. D., & Graff, J. R. (2000) · PubMed · Cited by 164
Self-citationRas mediates translation initiation factor 4E-induced malignant transformation.Preprint
Lazaris-Karatzas, A., Smith, M. R., Frederickson, R., Jaramillo, M., Yl, L., Kung, H. F., & Sonenberg, N. (1992) · Genes & Development · doi:10.1101/gad.6.9.1631 · Cited by 145
Ceramide As a Modulator of Endocytosis
Chen, C.-S., Rosenwald, A., & Pagano, R. E. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.13291 · Cited by 122
Elevated expression of eIF4E and FGF-2 isoforms during vascularization of breast carcinomas
Nathan, C. O., Carter, P., Liu, L., Li, B. D. �., Abreo, F. W., Tudor, A., Zimmer, S. G., & Benedetti, A. D. (1997) · Oncogene · doi:10.1038/sj.onc.1201272 · Cited by 122
Li, S., Takasu, T., Perlman, D., Peterson, M. S., Burrichter, D., Avdulov, S. V., Bitterman, P. B., & Polunovsky, V. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m208821200 · Cited by 115
Graff, J. R., Boghaert, E. R., Benedetti, A. D., Tudor, D., Zimmer, C. C., Chan, S. K., & Zimmer, S. G. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910600221 · Cited by 114
Self-citationRinker-Schaeffer, C. W., Graff, J. R., Benedetti, A. D., Zimmer, S. G., & Rhoads, R. E. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910550525 · Cited by 114
Self-citationTissue Disposition of 2′‐O‐(2‐methoxy) ethyl Modified Antisense Oligonucleotides in Monkeys
Yu, R. Z., Geary, R. S., Monteith, D., Matson, J. E., Truong, L., Fitchett, J. R., & Levin, A. A. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10473 · Cited by 114
Self-citationPostgenomic global analysis of translational control induced by oncogenic signaling
Rajasekhar, V. K., & Holland, E. C. (2004) · Oncogene · doi:10.1038/sj.onc.1207546 · Cited by 102
DeFatta, R. J., Nathan, C. O., & Benedetti, A. D. (2000) · The Laryngoscope · doi:10.1097/00005537-200006000-00007 · Cited by 100
Rapid induction of apoptosis mediated by peptides that bind initiation factor eIF4E
Herbert, T. P., Fåhræus, R., Prescott, A. R., Lane, D. P., & Proud, C. G. (2000) · Current Biology · doi:10.1016/s0960-9822(00)00567-4 · Cited by 97
Jackson, C., & Jenkins, K. L. (1991) · Experimental Cell Research · doi:10.1016/0014-4827(91)90194-y · Cited by 69
Larsson, O. S., Perlman, D., Fan, D., Reilly, C., Peterson, M., Dahlgren, C., Liang, Z., Li, S., Polunovsky, V. A., Wahlestedt, C., et al. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl558 · Cited by 64
Graff, J. R., Benedetti, A. D., Olson, J. W., Tamez, P. A., Casero, R. A., & Zimmer, S. G. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7592 · Cited by 47
Self-citationTranslation Initiation Factor 4E Blocks Endoplasmic Reticulum-mediated Apoptosis
Li, S., Perlman, D., Peterson, M. S., Burrichter, D., Avdulov, S. V., Polunovsky, V. A., & Bitterman, P. B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312467200 · Cited by 44
Aberrant type I and type III collagen gene expression in human breast cancerin vivo
Kauppila, S., Stenbäck, F., Risteli, J., Jukkola, A., & Risteli, L. (1998) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(1998110)186:3
Cited by
Regulation of Translation Initiation in Eukaryotes: Mechanisms and Biological Targets
Sonenberg, N., & Hinnebusch, A. G. (2009) · Cell · doi:10.1016/j.cell.2009.01.042 · Cited by 3,304
“Likewise, antisense oligonucleotides to eIF4E inhibit tumor growth in mice while not causing any deleterious effects (Graff et al., 2007).”
Tumor cell metabolism: cancer's Achilles' heel
Kroemer, G., & Pouyssegur, J. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.05.005 · Cited by 2,337
Targeting the translation machinery in cancer
Bhat, M., Robichaud, N., Hulea, L., Sonenberg, N., Pelletier, J., & Topisirovic, I. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4505 · Cited by 799
Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue
Gerdes, M. J., Sevinsky, C. J., Sood, A., Adak, S., Bello, M. O., Bordwell, A., Can, A., Corwin, A., Dinn, S., Filkins, R. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300136110 · Cited by 724
Targeting the mTOR Signaling Network for Cancer Therapy
Meric-Bernstam, F., & Gonzalez-Angulo, A. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0766 · Cited by 639
Metadata
- Authors
- Graff, J. R., Konicek, B. W., Vincent, T. M., Lynch, R. L., Monteith, D., Weir, S. N., Schwier, P., Capen, A., Goode, R. L., Dowless, M. S., Chen, Y., Zhang, H., Sissons, S., Cox, K., McNulty, A. M., Parsons, S. H., Wang, T., Sams, L., Geeganage, S., Douglass, L. E., Neubauer, B. L., Dean, N. M., Blanchard, K., Shou, J., Stancato, L. F., Carter, J. H., & Marcusson, E. G.
- Venue
- Journal of Clinical Investigation
- Published
- 2007-09-04
- Volume
- 117
- Issue
- 9
- Pages
- 2638-2648
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1968919723
- Cited by
- 380
- References
- 44
- FWCI
- 10.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.